Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-136 is a microRNA that acts as a tumor suppressor in various cancers, including glioblastoma. It functions by post-transcriptionally regulating gene expression, specifically targeting the 3'-untranslated region (UTR) of mRNAs such as CYR61 (Cysteine-rich angiogenic inducer 61). In glioblastoma models, miR-136 expression is up-regulated by the PPARα activator fenofibrate, leading to reduced cell proliferation. It has also been investigated for its role in other malignancies and biological processes like apoptosis and epithelial-mesenchymal transition (EMT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-136.